Kelun Pharmaceutical's Tirofiban Hydrochloride and Sodium Chloride Injection Passed the Consistency Evaluation

On March 4, Kelun Pharmaceutical issued an announcement stating that the "Drug Supplementary Application Approval Notice" for the chemical drug "Tirofiban Hydrochloride Sodium Chloride Injection" recently approved and issued by the National Medical Products Administration.

Product specifications:

100ml: tirofiban hydrochloride (calculated as C22H36N2O5S) 5mg and sodium chloride 0.

250ml: tirofiban hydrochloride (calculated as C22H36N2O5S) 12.

This product is mainly used for adult patients with non-ST-elevation acute coronary syndrome with ECG changes and/or myocardial enzyme elevation within 12 hours of the last chest pain onset, to prevent early myocardial infarction; and to plan direct PCI ( Percutaneous coronary intervention) in patients with acute myocardial infarction to reduce the occurrence of major cardiovascular events.

Tirofiban is a platelet glycoprotein IIb/IIIa receptor antagonist.